For the quarter ending 2026-03-31, COYA made $251,147 in revenue. -$7,206,990 in net income. Net profit margin of -2869.63%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 251,147 | 3,959,999 | 3,564,254 | 163,616 |
| Research and development | 4,096,580 | 4,940,495 | 2,916,875 | 3,663,103 |
| In-process research and development | 10,000 | 1,773,606 | 515,996 | - |
| General and administrative | 3,781,977 | 3,269,945 | 2,557,440 | 2,908,191 |
| Depreciation | 2,807 | 6,841 | 6,840 | 6,840 |
| Total operating expenses | 7,891,364 | 9,990,887 | - | 6,578,134 |
| Loss from operations | -7,640,217 | -6,030,888 | - | -6,414,518 |
| Other income | 433,227 | 325,435 | 317,066 | 319,541 |
| Pre-tax loss | -7,206,990 | -5,705,453* | - | -6,094,977 |
| Income tax (expense) benefit | - | 3,089* | - | 0 |
| Net loss | -7,206,990 | -5,708,542 | -2,115,831 | -6,094,977 |
| Basic EPS | -0.32 | -0.341 | -0.13 | -0.36 |
| Diluted EPS | -0.32 | -0.341 | -0.13 | -0.36 |
| Basic Average Shares | 22,644,304 | 16,742,821 | 16,732,766 | 16,724,998 |
| Diluted Average Shares | 22,644,304 | 16,742,821 | 16,732,766 | 16,724,998 |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)